BCYC
Bicycle TherapeuticsBCYC
BCYC
About: Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
Employees: 305
0
Funds holding %
of 7,431 funds
0
Analysts bullish %
of 4 analysts
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
1,000% more call options, than puts
Call options by funds: $407K | Put options by funds: $37K
93% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 14
76% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 21
13% more funds holding
Funds holding: 95 [Q1] → 107 (+12) [Q2]
1.29% less ownership
Funds ownership: 87.48% [Q1] → 86.19% (-1.29%) [Q2]
19% less capital invested
Capital invested by funds: $354M [Q1] → $286M (-$68.2M) [Q2]
33% less funds holding in top 10
Funds holding in top 10: 3 [Q1] → 2 (-1) [Q2]
Research analyst outlook
4 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$10
42%
upside
Avg. target
$23
227%
upside
High target
$44
525%
upside
4 analyst ratings
3 positive
75%
1 neutral
25%
0 negative
0%
JMP Securities Reni J. Benjamin | 42%upside $10 | Market Outperform Maintained | 12 Aug 2025 |
Morgan Stanley Jeffrey Hung | 85%upside $13 | Equal-Weight Maintained | 12 Aug 2025 |
Oppenheimer Jay Olson | 525%upside $44 | Outperform Maintained | 11 Aug 2025 |
RBC Capital Leonid Timashev | 255%upside $25 | Outperform Maintained | 17 Jul 2025 |
Financial journalist opinion
Neutral
The Motley Fool
2 weeks ago
Bicycle (BCYC) Q2 Revenue Falls 69%
Bicycle (BCYC) Q2 Revenue Falls 69%
Neutral
Business Wire
2 weeks ago
Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2025, and provided recent corporate updates. “We continue to execute on our strategy, which is grounded in scientific rigor and focused on fulfilling our mission to develop next-generation prec.
Neutral
Business Wire
1 month ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on July 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 77,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering i.
Neutral
Business Wire
2 months ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on June 2, 2025, the Compensation Committee of the company's Board of Directors granted to seven new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 57,700 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering i.
Neutral
Business Wire
3 months ago
Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting
CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the poster presentation of two abstracts at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago. Poster Presentation Details: Title: Phase 1/2 Duravelo-1 study: Preliminary results of Nectin.
Neutral
Business Wire
3 months ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on May 1, 2025, the Compensation Committee of the company's Board of Directors granted to 13 new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 79,500 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering into.
Neutral
Business Wire
3 months ago
Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported recent business progress and financial results for the first quarter ended March 31, 2025. “In the first quarter, we continued to advance our business priorities and our pipeline of oncology therapeutics. We were pleased to share additional human im.
Neutral
Business Wire
3 months ago
Bicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a biopharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, announced the presentation of additional human imaging data that validate the potential of MT1-MMP, a tumor antigen overexpressed in many cancers, as a novel target for cancer treatment and demonstrate the positive properties of Bicycle® Radioconjugates (BRC®).
Neutral
Seeking Alpha
4 months ago
Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted
Bicycle Therapeutics focuses on novel conjugated targeted therapies for cancer, with promising early results but no clear evidence of superior efficacy yet. Their lead compound, zelenectide pevedotin, shows potential in urothelial carcinoma with a 45% response rate, but more robust studies are needed. Financially, BCYC is well-capitalized with $879.5 million in cash, providing a runway into 2027 despite high operating expenses.
Neutral
Business Wire
4 months ago
Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), today announced that on April 1, 2025, the Compensation Committee of the company's Board of Directors granted to eight new employees inducement awards consisting of non-qualified share options to purchase an aggregate of 32,400 ordinary shares. These awards were made under Bicycle Therapeutics' 2024 Inducement Plan and approved by the Compensation Committee as an inducement material to the employees entering.
Charts implemented using Lightweight Charts™